0001140361-17-001760.txt : 20170112 0001140361-17-001760.hdr.sgml : 20170112 20170112215916 ACCESSION NUMBER: 0001140361-17-001760 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170110 FILED AS OF DATE: 20170112 DATE AS OF CHANGE: 20170112 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Emergent BioSolutions Inc. CENTRAL INDEX KEY: 0001367644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 141902018 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 BUSINESS PHONE: 240-631-3200 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DR, SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Abdun-Nabi Daniel CENTRAL INDEX KEY: 0001380187 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33137 FILM NUMBER: 17526319 MAIL ADDRESS: STREET 1: 400 PROFESSIONAL DRIVE STREET 2: SUITE 400 CITY: GAITHERSBURG STATE: MD ZIP: 20879 4 1 doc1.xml FORM 4 X0306 4 2017-01-10 0 0001367644 Emergent BioSolutions Inc. EBS 0001380187 Abdun-Nabi Daniel 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 1 1 0 0 President and CEO Common Stock 2016-08-01 4 J 0 1979 0.0 A 172945 D Common Stock 2016-08-01 4 J 0 3032 0.00 A 175977 D Common Stock 2016-08-01 4 J 0 3419 0.00 A 179396 D Common Stock 2017-01-10 4 M 0 38006 14.51 A 217402 D Common Stock 2017-01-10 4 S 0 28240 31.2782 D 189162 D Stock Option (Right to buy) 14.51 2016-08-01 4 J 0 3662 0 A 2017-03-08 Common Stock 3662 41668 D Stock Option (Right to buy) 14.51 2017-01-10 4 M 0 38006 0 A 2017-03-08 Common Stock 38006 3662 D In connection with the spin-off (the "Spin-off") of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc. ("Emergent"), on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the Spin-off. The restricted stock units vest in March 2017. In connection with the spin-off on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018. In connection with the spin-off the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.91 to $32.26, inclusive. Represents options to purchase Emergent common stock awarded to the reporting person prior to the Spin-off . In connection with the Spin-off, the number of shares and exercise price of the option was adjusted, to preserve the pre-Spin-off intrinsic value of the existing Emergent option award. Consists of an option granted under the company's stock incentive plan as amended and restated prior to the Spin-off. The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. /s/ Eric Burt, Attorney-in-fact 2017-01-10